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Abstract
Background: Studies show that Toll-like receptors (TLRs), members of the innate immune system, might participate
in the pathogenesis of the major depressive disorder (MDD). However, evidence of this participation in the brain of
patients with MDD has been elusive.
Methods: This work explores whether the protein expression by immunodetection assays (Western blot) of elements
of TLR-4 pathways controlling inflammation and the oxidative/nitrosative stress are altered in postmortem dorsolateral
prefrontal cortex of subjects with MDD. The potential modulation induced by the antidepressant treatment on these
parameters was also assessed. Thirty MDD subjects (15 antidepressant-free and 15 under antidepressant treatment)
were matched for gender and age to 30 controls in a paired design.
Results: No significant changes in TLR-4 expression were detected. An increased expression of the TLR-4 endogenous
ligand Hsp70 (+ 33%), but not of Hsp60, and the activated forms of mitogen-activated protein kinases (MAPKs)
p38 (+ 47%) and JNK (+ 56%) was observed in MDD. Concomitantly, MDD subjects present a 45% decreased expression
of DUSP2 (a regulator of MAPKs) and reduced (− 21%) expression of the antioxidant nuclear factor Nrf2. Antidepressant
treatment did not modify the changes detected in the group with MDD and actually increased (+ 25%) the expression
of p11, a protein linked with the transport of neurotransmitters and depression.
Conclusion: Data indicate an altered TLR-4 immune response in the brain of subjects with MDD. Additional research
focused on the mechanisms contributing to the antidepressant-induced TLR-4 pathway modulation is warranted and
could help to develop new treatment strategies for MDD.
Keywords: Major depression, Postmortem frontal cortex, Antidepressants, Neuroinflammation, Toll-like receptor
4 pathway, Mitogen-activated protein kinases, Nrf2 pathway
Background
Many studies are focusing on identifying new etiopatho-
logical trails and therapeutic targets of depression. One
promising development is the apperception of the inflam-
mation, both in the brain and periphery, as an element
worth to consider in the pathogenesis of major depressive
disorder (MDD). This concept is grounded in the detec-
tion of activated inflammatory/immune response in this
disease [1, 2] both in the brain and in the periphery.
Studies demonstrate that MDD is associated with
manifestation of inflammatory markers [3]. Moreover,
meta-analyses show increased inflammatory parameters
in the blood of patients with MDD [4, 5]. Alternatively,
patients undergoing cytokine therapy develop depressive
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symptoms [6, 7] and experimental-induced inflammation
promotes mood deterioration in healthy subjects [8]. Fur-
thermore, elevated inflammatory markers predict a poorer
response to antidepressants (AD) while non-responding pa-
tients to AD show persistently elevated inflammation [9].
Currently, increasing attention is being paid to the poten-
tial role of the innate immune system in the pathogenesis
of psychiatric diseases, particularly to Toll-like receptors
(TLRs) [10]. TLRs trigger a complex proinflammatory
cascade that can regulate central nervous system (CNS)
homeostasis and even promote pathology [11]. TLRs are
expressed not only in immune cells, but also in neurones,
astroglia, and resident microglia [12–14]. Their ubi-
quitous distribution suggests that TLRs play other
roles in non-pathogen-associated CNS diseases/injuries,
presumably through recognizing endogenous molecules
released from damaged tissues, also known as damage-as-
sociated molecular patterns (DAMPs) (e.g., heat shock pro-
tein Hsp60, Hsp70) [15].
Most of studies have focused on TLR-4, which responds
predominantly to lipopolysaccharide (LPS), a component of
the outer membrane of Gram-negative bacteria [16]. TLR-4
triggers a transduction pathway (i.e., specific kinases includ-
ing mitogen-activated protein kinases —MAPKs) resulting
in the activation of inflammatory nuclear transcription fac-
tors [17]. Many of the MAPK pathway downstream targets
are transcription factors that coordinate the transcription
of several genes encoding inflammatory mediators, such
as cytokines, chemokines, and inducible pro-oxidative en-
zymes [17].
Despite the considerable evidence suggesting active in-
flammatory pathways in MDD, confirmation of abnormal-
ities in the postmortem brain of affected subjects has been
in some way elusive. Increased cytokine and chemokine
gene expression and/or concentrations have been shown in
the frontal cortex of MDD subjects [18–21]. Aditionally, al-
tered microglial kynurenines have been described in the
cingulate gyrus and hippocampus of MDD [22, 23] and an
astrocytic hypertrophy in the anterior cingulate white mat-
ter of depressed suicides has been reported [24]. Moreover,
a recent study employing dentate gyrus proposes neuroin-
flammation as crucial in MDD [25].
An important limitation in brain postmortem studies is
the possibility that presence of antidepressant treatment
could affect the expression and function of cytokines and
other inflammatory factors. Most of the previous postmor-
tem studies were performed under experimental condi-
tions that were not designed to control for this factor.
The present work aims to study whether specific ele-
ments of intracellular pathways controlling inflamma-
tion along with factors related to the restraining of the
oxidative/nitrosative stress (i.e., the nuclear factor Nrf2)
are altered in postmortem dorsolateral prefrontal cor-
tex of subjects with MDD. In particular, this study has
focused on innate immunity-related elements ordinarily
understudied and novel parameters such as MAPKs and
the antioxidant nuclear factor Nrf2 pathways, respectively.
The potential modulation induced by the antidepressant
treatment on these parameters was also assessed.
Methods
Postmortem human brain samples
Human brain samples from dorsolateral prefrontal cortex
(Brodmann’s area 9) were obtained at autopsy in the Basque
Institute of Legal Medicine, Bilbao, Spain, in compliance
with research policies and ethical committees for post-
mortem brain studies. After a retrospective search for
antemortem medical information, 30 Caucasian sub-
jects diagnosed with MDD (DSM-IV, DSM-IV-R, or
CIE-10 criteria) were matched for ethnic origin, gender,
and age (± 4 years) to 30 control subjects in a paired
design. Since non-compliance is frequently observed,
the absence or presence of antidepressant drugs was de-
fined according to the toxicological screening at the time of
death. Thus, MDD subjects were divided into two groups:
subjects antidepressant-free at time of death (AD-free;
n = 15) and subjects antidepressant-treated at time of
death (AD-treated; n = 15), see Additional file 1 for full
details about sample and demographic information.
Preparation of nuclear and cytosolic extracts
A widely utilized method that provides a high purity nu-
clear fraction, practically without cytosolic contamination
[26] was used (see Additional file 1).
Western blot analysis
The expression levels of TLR-4, Hsp60, Hsp70, phospho-
ERK 1/2, phospho-JNK, phospho-p38, p38 α/β, PI3K,
Keap-1, and S100A10 (p11) in cytosolic extracts and the
expression levels of DUSP-2, Nrf-2, and p65 (NF-κB sub-
unit) in nuclear extracts from brain samples were analyzed
through Western blot (see Additional file 1).
Protein assay
Protein levels were measured using Bradford method based
on the principle of protein-dye binding.
Chemicals and statistical analyses
Unless otherwise stated, the chemicals were from Sigma-
Aldrich (Spain).
Estimation of the sample size was drawn from previous
postmortem studies of neuroinflammation, apoptosis,
and oxidative/nitrosative stress in schizophrenia [27]
and MDD [28].
Data are expressed as mean ± SEM. Protein expression
data were normalized for respective endogenous control
expression (β-actin or GAPDH) and relative to a reference
standard (pool of control samples), whose expression level
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was defined as 100%. The quantification procedure was
repeated three times for each pair of subjects in different
gels. The mean value of the different gels was used as a
final estimate.
Unpaired two-tailed t test was performed when com-
paring controls vs MDD and a two-tailed t test with
Welch’s correction was employed when samples did not
have equal standard deviations. After completion of the as-
says, since the control groups for AD-free and AD-treated
subjects did not differ from each other for confounding fac-
tors (see Additional file 1: Table S1), they were pooled for
further statistical analyses. One-way ANOVA with a Fisher’s
LSD post hoc test was used to compare between controls
and AD-free and AD-treated MDD groups. Data were ana-
lyzed using the Brown-Forsythe test to assess the Gaussian
distribution. In cases in which data did not follow a Gauss-
ian distribution, a Kruskal-Wallis test followed by post hoc
Dunn’s test was performed. Correlations were performed to
evaluate the influence of the postmortem delay, storage
time, and body mass index (BMI). When positive, the
results were tested by ANCOVA with the corresponding
factor as covariate. In all the cases, a p value < 0.05 was
considered statistically significant.
Results
The different groups of controls, AD-free and AD-treated
subjects at time of death, were comparable attending to
gender ratio, age, postmortem delay (PMD), storage time,
brain pH RNA integrity number (RIN), and blood ethanol
concentrations (Additional file 1: Table S1). BMI was
lower in MDD subjects than that in controls (Add-
itional file 1: Table S1). Age at death significantly corre-
lated only with Hsp70 expression (r = 0.54, p = 0.004).
This demographic factor did not influence results due to
the matched paired design. BMI showed inverse correl-
ation with p-p38 (r = − 0.35, p = 0.007), ratio p-p38/total
p38 (r = − 0.36, p = 0.005), and Keap-1 (r = − 0.28, p =
0.04) expression and positive correlation with NF-κB
p65 expression (r = 0.31, p = 0.04). There was also a posi-
tive correlation between PMD and Hsp60 expression (r =
0.28, p = 0.03). Ethanol concentrations displayed signifi-
cant correlation (r = 0.43, p = 0.003) with S100A10 (p11).
Other drugs than antidepressants did not show influ-
ence on inflammatory and antioxidant parameters.
Effects of MDD and antidepressant treatment on the
expression of TLR-4 and its endogenous ligands Hsp60
and Hsp70
TLR-4 expression analyses revealed no significant differ-
ences between controls and subjects with MDD (Fig. 1a, b).
There were no statistical differences either when the
protein expression values of heat shock protein Hsp60
were analyzed (Fig. 1c, d). The results would not change
when controlled for PMD effect. Conversely, subjects with
MDD in bulk showed a significant 33% increase in the
Hsp70 protein expression compared with controls (Fig. 1e).
When the AD-free and the AD-treated at time of death
groups were split, but both groups maintained a trend to
show higher values than control group however without
statistical significance (Fig. 1f).
Effects of MDD and antidepressant treatment on the
expression of MAPKs and the MAPK activity regulator
DUSP2
Subjects with MDD showed an increased expression of
the activated (phosphorylated) forms of the extracellu-
lar signal-regulated kinases (ERK)1/2 (+ 22%, t = 2.293,
p = 0.03) and the c-Jun N-terminal kinases (JNK) (+
56%, t = 2.468, p = 0.02) but not the p38 MAPK (+ 19%,
t = 1.317, p = 0.19) compared with matched controls
(Fig. 2a, c). The activated forms of ERK1/2 and JNK in-
creased in the AD-treated group when compared with the
controls. Although phospho-p38 inversely correlates with
BMI, ANCOVA demonstrated that controlling for this
factor did not influence the results. When considering the
ratio between the phosphorylated and the total forms of
the proteins, the increase for p-ERK1/2/total ERK1/2 did
not reach statistical significance whereas p-JNK/total JNK
and p-p38/total p38 were clearly higher in MDD than in
controls (Fig. 2e). The phosphorylated forms and ratios for
p-ERK1/2/total ERK1/2, p-JNK/total JNK, and p-p38/total
p38 were selectively increased in AD-treated subjects al-
though did not reach statistical significance in the case of
p-ERK1/2/total ERK1/2 ratio (Fig. 2b, d, f ). ANCOVA
controlling for BMI did not modify p-p38/total p38
ratio results.
Dual-specificity phosphatase 2 (DUSP2) regulates MAPK
activity. DUSP2 expression decreased by 45% in MDD
compared with matched controls (Fig. 2g). The statistical
difference was retained both in the AD-free at time of death
and the AD-treated groups when compared with controls
(Fig. 2h).
Effects of MDD and antidepressant treatment on the
antioxidant nuclear factor (erythroid 2-derived)-like 2
(Nrf2) pathway
The PI3K (phosphoinositide 3-kinase) is an activator of the
antioxidant transcription factor Nrf2. Subjects with MDD
presented an unaltered PI3K expression when compared
with controls (Fig. 3a, b).
The Keap-1 (Kelch-like ECH-associated protein 1) is
the cytoplasmic inhibitor of Nrf2. Subjects AD-free and
AD-treated at time of death showed a non-significant in-
crease in the expression of Keap-1 when compared with
controls (Fig. 3c, d). Results of Keap-1 were not modi-
fied when controlling for BMI.
Subjects with MDD showed a 21% decrease of nuclear
expression of Nrf2 (Fig. 3e). Statistical significance in the
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analysis of variance was observed only in the AD-treated
group, which showed a 31% decrease of nuclear expres-
sion of Nrf2 compared with controls (Fig. 3f ).
Effects of MDD and antidepressant treatment on the
expression of S100A10 (p11)
The S100A10 (also known as p11) is a multifactorial pro-
tein linked with the transport of neurotransmitters and
depression. There were no significant differences between
the control and the MDD groups (Fig. 4a). However, when
considering MDD subjects according to antidepressant
treatment, p11 was elevated in the AD-treated group
compared with the AD-free at time of death and the con-
trol groups (Fig. 4b). ANCOVA controlling for ethanol
concentrations, maintained the significance of p11 incre-
ment in MDD.
Effects of MDD and antidepressant treatment on the
expression of NF-κB
The p65 subunit of the transcription factor NF-κB, which
controls the transcription of many acute-phase proteins
and inflammatory genes [29], was analyzed, showing de-
creased expression in subjects with MDD (Fig. 4c), both in
AD-free (− 46%) and AD-treated (− 38%) groups at time
of death (Fig. 4d). When results were controlled for BMI
of the subjects, which has well-known effects on neuroin-
flammation [30], ANCOVA analysis failed to show statis-
tical significance (p = 0.09).
Discussion
The present work points to an alteration of inflamma-
tory and oxidative/nitrosative pathways in the brain of
subjects with MDD. Different cytoplasmic and nuclear
factors involved in neuroinflammatory processes such as
constituents of innate immunity response, elements of
the antioxidant Nrf2 pathway, and transcription factors
were assessed. Data indicate that the overexpression of
proinflammatory MAPK pathways is associated with AD
treatments, something partially described in in vitro and
in vivo experimental settings [31–34] and in postmortem
brain of subjects with MDD [28].
In the CNS, the innate immunity receptor TLR-4 is
expressed in microglia, neurones, astroglia, oligodendroglia,
and cerebral vascular endothelium [35]. Altered TLR-4 sig-
naling has been described in peripheral blood cells and the
brain of patients with schizophrenia, bipolar disease, and
depression [10]; in postmortem brain of subjects with
schizophrenia [27, 36]; and in stress animal models [10].
Fig. 1 Effects of MDD and antidepressant treatment on the expression of TLR-4 and its endogenous ligands Hsp60 and Hsp70. There were no differences
in the protein expression of TLR-4 among controls and subjects with MDD (a, b). There were no statistical differences between groups in the protein
expression values of Hsp60 (c, d). Subjects with MDD showed a significant 33% increase in the Hsp70 protein expression compared with controls (e).
The statistical significance disappeared when the AD-free at death and the AD-treated groups were split, but both groups maintained a trend to show
higher values than control group (f). The densitometric data of the band of interest were normalized by beta-actin. Some blots were cropped (black lines)
for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p< 0.05 vs. control; unpaired two-tailed t test was performed when
comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD
groups. See the “Chemicals and statistical analyses” section for more details
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Fig. 2 Effects of MDD and antidepressant treatment on the expression of MAPKs and on the expression of the MAPK activity regulator DUSP2. When
considering the phosphorylated forms of the proteins, p-ERK1/2, p-JNK, and the ratio between p-p38/total p38 were clearly higher in MDD than in controls
(a, c, e). The expression values were selectively increased in AD-treated subjects (b, d, f). Analysis of covariance controlling for BMI did not modify p-p38/
total p38 ratio results. DUSP2 expression was decreased in MDD compared with matched controls (g), and this statistical difference appeared both in the
subjects AD-free at time of death and in AD-treated subjects when compared with controls (h). The densitometric data of the band of interest were
normalized by beta-actin. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM;
*p < 0.05, **p < 0.01 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post
hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for
more details
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There are two predominant sources of TLR-4 activation: (i)
altered gut microbiota [37] and the subsequent dysbiosis
through increased intestinal barrier permeability and bac-
terial translocation present in patients with MDD [38, 39],
and (ii) damage-associated molecular patterns (DAMPs) re-
leased by non-infective tissue injuries [40]. Among these
DAMPs, the heat shock protein Hsp60 and the Hsp70 are
well-known stimulators of the TLR-4 [16]. The present re-
sults indicate that TLR-4 expression was not noticeably
induced in MDD subjects, at least at the moment when
the samples were taken. These results also show that the
treatment with antidepressants (AD-treated group) tends
to decrease TLR-4 expression in the brain. Increased
mRNA expression of TLR-4 and later reduction below
control levels after AD treatment have been recently de-
scribed in peripheral blood cells of patients with MDD
[41]. In the dorsolateral prefrontal cortex of depressed
subjects, TLR-4 increased mRNA expression has been
previously found together with an unaltered TLR-4 pro-
tein expression in non-suicide victims and elevation in
suicide victims [42]. In this previous study, although the
influence of AD treatment was considered, a controlled
design for this purpose was not included which prevents
from drawing definitive conclusions. Consistent with the
hypothesis of a DAMP activation of TLR-4 pathways in
MDD, evidence of enhanced Hsp70 protein expression is
here provided. No differences in Hsp70 expression are ob-
served between AD-free at time of death and AD-treated
subjects, suggesting that elevation of the endogenous lig-
and Hsp70 is rather associated to the disorder and that
downregulation of the TLR-4 receptor after AD treatment
represents the compensatory effect against the hyperactive
pathway. An equivalent observation has been found for
the Hsp70 family member GRP78 in postmortem brain of
depressed suicide victims [43]. Whether increased
Hsp70 expression represents a dysfunction originated
in the periphery or a primary CNS impairment re-
mains to be elucidated.
The MAPKs are downstream elements activated after
TLR-4 stimulation [17, 44]. The MAPK pathways are
implicated in a wide range of signaling cascades wherein
various extracellular stimuli induce inflammation. It has
been shown that MAPKs can play as well an important
role in the regulation of the NF-κB pathway [45]. More-
over, proinflammatory cytokines can increase, through
activation of signaling pathways that include MAPKs,
the expression and function of monoamine transporters
[46, 47], the most important target for antidepressant
Fig. 3 Effects of MDD and antidepressant treatment on the antioxidant nuclear factor (erythroid 2-derived)-like 2 (Nrf2) pathway. Subjects with MDD
presented a non-significant trend to decrease (− 18%) the Nrf2 activator PI3K expression when compared with controls, being the decrease in the
expression more pronounced in the AD-treated group (a, b). Subjects AD-free and AD-treated at death showed a non-significant trend
towards a 16–18% increase in the expression of the cytoplasmatic inhibitor of Nrf2 Keap-1 protein when compared with controls (c, d).
Subjects with MDD showed a significant decreased nuclear expression of Nrf2 (e). AD-treated group showed a decreased nuclear expression of Nrf2
compared with controls (f). The densitometric data of the band of interest were normalized by beta-actin or GAPDH for the cytoplasmic or nuclear
fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM;
*p < 0.05 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test
was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more details
Martín-Hernández et al. Journal of Neuroinflammation  (2018) 15:251 Page 6 of 12
drugs. In this context, genes related to MAPK pathways
seem to be upregulated by chronic antidepressant treat-
ment [33]. Data suggest increased expression of the acti-
vated forms of ERK1/2, JNK, and p38 proteins in MDD.
When the MDD group is evaluated considering the pres-
ence of AD drugs, the elevation is mainly observed in
AD-treated subjects. Thus, the presence of AD treat-
ment might be associated with an overactivation of
MAPK pathways.
Changes in basal ERK activation produce structural
changes in neurones responsible for phenotypes of mood
disorders [48]. ERK has been related to the regulation of
gene expression and protein synthesis, shifts in the cellular
structure and metabolism, cell differentiation and apoptosis.
All these regulatory effects might play a role in the im-
pairments of neural plasticity, neurogenesis, and cellu-
lar resilience described in the brain of subjects with
depression [49]. Furthermore, the effectiveness of drugs
such as mood stabilizers and antidepressants partially
depends on their capacity to stimulate ERK in the CNS
[49, 50]. In postmortem frontal cortex of suicide vic-
tims with MDD, mainly in AD-free conditions, a de-
creased expression and activation of total ERK1/2 has
been previously described [51]. Another study in post-
mortem brain has found unaltered total ERK1/2 protein
expression with decrease of active p-ERK1/2 forms that
are normalized under AD treatment [28]. These data
are quite consistent with results in rats exposed to
stress where chronic fluoxetine reversed the lower
p-ERK1/2 protein expression in the hippocampus and
frontal cortex [32]. Accordingly, in the present study, sub-
jects AD-free at time of death show a non-significant
dropping tendency (− 26%) of total ERK1/2 expression
when compared to controls whereas only a 7% reduction
is obtained in AD-treated (data not shown). On the other
hand, the expression of p-ERK1/2 (activated) form and
p-ERK1/2/total ERK1/2 ratio is markedly increased in
MDD subjects under AD treatment. Thus, AD treatment
seems to promote expression of activated ERK forms, pos-
sibly in an attempt to recover the plasticity and counteract
the negative cellular effects associated with the reduced
expression of ERK observed in the disorder.
An increased expression of the activated forms of JNK
and p38 in subjects with MDD is shown here. Import-
antly, their expression follows the same pattern as the ex-
pression of ERK, being higher in the AD-treated group.
Fig. 4 Effects of MDD and AD treatment on the expression of S100A10 (p11) and NF-κB. There were no significant differences in the p11 expression
between control and MDD groups (a). p11 was elevated in the AD-treated at death group compared with the AD-free at death and the control groups
(b). The p65 subunit of the transcription factor NF-κB expression was decreased in patients with MDD compared with controls (c) and when AD-free and
AD-treated at death groups were compared with matched controls (d). The densitometric data of the band of interest were normalized by beta-actin or
GAPDH for the cytoplasmatic or nuclear fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the
presentation. Data are means ± SEM; *p < 0.05, **p < 0.01 vs. control; #p < 0.05 vs. AD-free; unpaired two-tailed t test was performed when comparing
controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups.
See the “Chemicals and statistical analyses” section for more details
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Both p38 and JNK have been linked to the pathophysi-
ology of depression [52]. Specifically, p38 has been re-
lated to MDD because of its proinflammatory actions
and its stimulatory activity on the expression and
function of the serotonin transporter [2]. JNK plays a
critical role in the regulation of T lymphocyte differ-
entiation and cytokine production [52]. Inhibition of
the JNK pathway in animal models of depression [53]
and activation of p38-dependent pathways by the anti-
depressant amitriptyline [54] have been previously de-
scribed. Further research is needed to evaluate the
role of these MAPKs in MDD and their modulation by
AD drugs.
Dual-specificity phosphatases (DUSPs) are a heteroge-
neous group of protein phosphatases that regulate activity
of MAPKs through dephosphorylation (deactivation) and
serve to control the MAPK subcellular localization [55].
DUSP2 displays substrate specificity for ERK, p38, and
JNK. In fact, preclinical in vivo studies revealed that DUSP2
is a negative regulator of JNK activity and positive regulator
of immune responses via cross-talk between JNK and ERK
[56]. The present results show a decrease in DUSP2 expres-
sion in the MDD group, both in subjects AD-free and
AD-treated at time of death. This result could explain, at
least partially, the trend towards enhanced MAPK expres-
sion in MDD.
Nrf2 is a main cellular defense pathway activated by oxi-
dative stress, leading to production of target antioxidants
[57]. A role for the Nrf2 pathway in experimental models
of depression has been described [58, 59]. Thus, Nrf2 null
mice are more vulnerable to develop depression-like
phenotypes [60]. Indeed, Nrf2 has been proposed as a
potential therapeutic target worth to consider in future
studies [61]. Our data indicate a decrease of the Nrf2
pathway in subjects with MDD. This decrease would be
in agreement with the proposed role of Nrf2 in the
pathophysiology of depression, being involved in the
enhanced oxidative/nitrosative stress described in this
disorder [62]. Antidepressant treatment affected the
nuclear expression of Nrf2. Previous preclinical stud-
ies showed that antidepressants modulate this pathway
and that this effect differs depending of the CNS re-
gion analyzed [59]. Moreover, there are results in hu-
man monocytic U-937 cells, suggesting that the effects
of AD on the expression of antioxidant enzymes are
dependent on the duration of the treatment and even
can have pro-oxidant consequences [63]. Here, AD
treatments do not reverse the trend to reduction ob-
served in AD-free at time of death subjects and even
could be negatively affecting the Nrf2 protective path-
way. The possibility that both groups of subjects could
represent a population with resistance to AD should
Fig. 5 Schematic representation of the pathways being affected by MDD and by treatments. Inflammatory pathway studied (a) and results obtained (b).
In b, the colors show the statistically significant changes in major depressive disorder (MDD) vs. control group (red = upregulation, blue =
downregulation). The arrows indicate the effects on the MDD group treated with antidepressants at time of death (AD-treated group). TLR
Toll-like receptor, Hsp Heat shock protein, MyD88 myeloid differentiation primary response 88, MKK mitogen-activated protein kinase kinase,
ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, p38 protein 38, NF-κB nuclear factor kappa B, 5-HTR serotonin receptor,
p11 S100 calcium-binding protein A10 (S100A10), DUSP2 dual-specificity phosphatase 2, Nrf2 nuclear factor (erythroid 2-derived)-like 2, Keap-1
Kelch-like ECH-associated protein 1, PI3K phosphoinositide 3-kinase, P phosphate
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bear in mind due to the presence of suicide as the
main cause of the death. The downward trend in the
expression of the Nrf2 activator PI3K and increased
expression of the Nrf2 inhibitor Keap-1 both in
AD-free and AD-treated populations at time of death
is congruent with the nuclear reduction of this tran-
scription factor.
The calcium-binding protein p11 is linked with the trans-
port of neurotransmitters and depression and data from cell
lines confirm that it is regulated by immunological parame-
ters like TLR-4 [64]. Administration of proinflammatory cy-
tokines stimulates the formation of p11 through unknown
mechanisms [65]. Experimental data indicate that p11
knockout mice display a depressive-like phenotype whereas
p11 overexpressing mice display antidepressant-like re-
sponses [66]. Moreover, p11 is upregulated in the CNS after
chronic antidepressant treatments. Once upregulated, p11
increases the expression of 5-HT receptors on the plasma
membrane, providing an enhancer mechanism for anti-
depressant actions [67]. Our results show a specific aug-
mentation of p11 protein expression in the AD-treated
group compared with the AD-free group at time of death
and controls. The data agree with prior results in animal
models of depression and humans suffering with MDD
where decreased p11 expression was reported [66]. How-
ever, it is the first evidence showing that AD treatment may
result in increased p11 protein expression reported for
MMD subjects.
NF-κB is a nuclear factor that controls the transcription
of many acute-phase proteins and inflammatory genes, be-
ing one of the early events in the stress-induced inflam-
matory response in CNS [26]. Although hyperactive
NF-κB in peripheral cells has been considered a finger-
print of stress and mood disorders, in animals under
chronic mild stress conditions, small reductions of NF-κB
p65 mRNA and protein expression and activity have been
described [26]. The present study suggests a similar ten-
dency in the human brain. However, control subjects ex-
hibited a higher BMI, a physical parameter that displayed
positive relationship with NF-κB expression. Therefore,
larger studies of controlled populations for BMI are neces-
sary to establish definitive conclusions on the status of
NF-κB in the brain of subjects with MDD. Besides, NF-κB
is not only a main regulator of the inflammatory response
but is also an essential regulatory element of cell survival,
controlling key processes such as neuroprotection, neur-
onal transmission, and plasticity [68]. Once again, more
studies are warranted in order to fully understand the role
of NF-κB in this particular setting.
Suicide represents a special cause of death that may
act as a confounding factor in studies using postmortem
brain samples from subjects with psychiatric disorders.
Since suicide is highly prevalent in depressive disorders,
the neurobiology underlying suicide might mask some
results in MDD studies. Therefore, the assumption that
description of inflammation pathways altered in the
brain of depressed suicide victims can automatically be
extended to depressed non-suicide victims is potentially
faulty. In fact, case points of differences between suicide
and non-suicide depressed subjects for TLR-4 [42] and
microglial density [69] have been published. Moreover,
MDD subjects died by suicide and under confirmed
antidepressant treatment, as herein presented, should be
considered more representative of resistant than stand-
ard depression. Although suicide was the cause of death
for an important number of MDD subjects in the
present study, opposite results for TLR-4 and NF-κB ex-
pression have been recently described in a schizophrenia
population mainly dead by suicide [27]. Therefore, at
least some of the changes herein observed in the post-
mortem brain of MDD subjects should be associated to
depression and antidepressant treatment rather than to
suicide behavior. About 4% of depressed individuals die
by suicide, being the risk greater in males [70]. Although
depression is more prevalent in female, this factor could
explain the higher presence of male subjects in the
present study.
The fact that selection of MDD subjects was performed
based on clinical records of subjects could be interpreted as
a study limitation. In fact, the use of antemortem diagnosis
versus postmortem retrospective methodologies based on
psychological autopsy is still a matter of controversy [71].
The psychopathological condition of MDD and control
subjects at time of death represents also a limitation of this
type of studies performed in outpatients who die by sudden
and unexpected causes. On the other hand, although con-
trol subjects did not show clinical records of neurological
or psychiatric disorders, including drug abuse, the possibil-
ity of presence of potential non-diagnosed subjects among
controls is not completely ruled out. For a better interpret-
ation of the alterations caused by MDD and the actions of
antidepressant treatments see Fig. 5.
Conclusions
Our results show an increase in Hsp70, an endogenous lig-
and of the TLR-4 and in the products of the TLR-4 activa-
tion such as MAPKs in postmortem dorsolateral prefrontal
cortex of subjects with MDD. An important effect to con-
sider is the influence of the pharmacological treatment with
AD on MAPK expression. Further research focused on
the mechanisms that contribute to this modulation is
essential and could help developing new treatment
strategies for MDD.
Results also show for the first time in the brain of MDD
subjects that the disorder is affecting the antioxidant Nrf2
pathway. In particular, a decrease in the antioxidant factor
Nrf2 is observed. Complementary, AD treatment induces
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an increase of p11 that could be boosting the expression of
5-HT receptors.
The data seem to point out to the presence of an altered
innate immune response in the brain of subjects with
MDD, in whom the TLR4 pathway could be one of the
main elements influenced. However, Hsp70 also binds to
other TLRs as well as other receptors and therefore add-
itional studies are required to explicitly confirm TLR-4
involvement. Similarly, further research is necessary to as-
certain the condition of the innate immune system in the
MDD and attending especially to the potential confounding
factor of antidepressant treatment.
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